CARsgen Therapeutics (HKG:2171) presented the updated results of three drugs at the 66th Annual Congress of the American Society of Hematology, a Tuesday bourse filing said.
Two of the drugs, CT0590 and CT071, are currently being tested for the treatment of relapsed/refractory multiple myeloma, while Zevorcabtagene autoleucel has been approved for the same purpose by China's National Medical Products Administration.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。